Medical Information
Saudi Arabia
 

This medical Information website is intended only for Healthcare Professionals in the Kingdom of Saudi Arabia. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Please choose the category that best describes you.

This content is intended for Healthcare professionals in Saudi Arabia. Would you like to proceed?

I am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
SelectI am a healthcare professional registered to practice in KSAYes, I am a healthcare professional registered to practice in KSA
I am not a healthcare professionalNo, go back to the patient portal
SelectI am not a healthcare professionalNo, go back to the patient portal
Non-Saudi Arabia residents click here.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Oral Presentation
Finn RS, Rugo HS, Dieras V, Harbeck N, Im S-A, Gelmon KA, Walshe JM, Martin M, Chavez-MacGregor M, Bananis E, Gauthier E, Lu DR, Kim S, Slamon DJ June 4, 2022 ASCO 2022 Breast Cancer

Overall Survival (OS) With First-Line Palbociclib Plus Letrozole (PAL+LET) Versus Placebo Plus Letrozole (PBO+LET) in Women with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer (ER+/HER2− ABC): Analyses From PALOMA-2

View Presentation View Abstract Plain Language Summary
Poster
Yeh C, Zhou M, Bapodra N, Rivero M, Espinal-Dominguez E, Moran M, Hershman DL, Fojo T, Bates SE June 6, 2022 ASCO 2022 Breast Cancer

A Novel Analysis of Data From the PALOMA-3 Trial Confirms the Efficacy of Palbociclib and Provides an Option for Efficacy Assessments that Could Accelerate Drug Approvals

View Presentation View Abstract Plain Language Summary
Poster
Pascual J, Martin M,   Proszek P,   Gil-Gil M,   Reay A,   Zielinski C,   Herranz J, Cutts R, Ruiz-Borrego M, Feber A, Ciruelos EM, Swift C, Munoz M, Bermejo B, Margeli M, Li Y, García-Murillas I,   Hubank M, Turner NC June 6, 2022 ASCO 2022 Breast Cancer

Baseline and Longitudinal ctDNA Biomarkers in GEICAM/2013-02 (PEARL) Trial Cohort 2 Comparing Palbociclib and Fulvestrant (PAL + FUL) versus Capecitabine (CAPE)

View Presentation
Poster
Hu X, Broughton E, Li W, Sun T, Shen K, Huang C-S, Sriuranpong V, Ngan KCR, Chia YH, Bhattacharyya H, Zhao H, Shen J, Xu B September 10, 2022 ESMO 2022 Breast Cancer

Patient-Reported Quality of Life in Patients With Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole: Results From PALOMA-4

View Presentation View Abstract Plain Language Summary
Poster
Tripathy D, Rocque GB, Blum JL, Karuturi MS, McCune S, Kurian S, Moezi M, Anderson D, Gauthier E, Zhang Z, Montelongo MZ, Wang Y September 10, 2022 ESMO 2022 Breast Cancer

Real-World Clinical Outcomes of Palbociclib Plus Endocrine Therapy in Hormone Receptor–Positive Advanced Breast Cancer: Results From the POLARIS Trial

View Presentation View Abstract Plain Language Summary
Poster
Rocque G, Blum JL, Ji Y, Pluard T, Migas J, Lakhanpal S, Jepsen E, Gauthier E, Wang Y, Montelongo MZ, Cappelleri JC, Karuturi MS, Tripathy D September 10, 2022 ESMO 2022 Breast Cancer

Real-World Quality of Life in Patients With HR+/HER2– Advanced Breast Cancer Treated With Palbociclib: Final Clinical Outcome Assessment Analysis From POLARIS

View Presentation View Abstract Plain Language Summary
Poster
Karam J, Rejto P, Bienkowska JR, Mu XJ, Roh W April 18, 2023 AACR 2023 Breast Cancer

Identification of Tumor-Specific Breast Cancer Expression Subtypes and Subtype-Specific Drug Response Prediction

View Presentation